Modified vaccinia ankara

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Modified vaccinia ankara
Accession Number
DB15483
Description
Not Available
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Modified Vaccinia Virus (Ankara-Bavarian Nordic)
  • MVA
  • MVA-BN
  • Vaccinia strain modified ankara

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ImvamuneSuspensionSubcutaneousBavarian Nordic As2015-06-15Not applicableCanada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
TU8J357395
CAS number
Not Available

References

General References
Not Available
Not Available
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionVaccinations1
3Active Not RecruitingPreventionEbola Virus Disease1
3Active Not RecruitingPreventionHemorrhagic Fever, Ebola1
3Active Not RecruitingPreventionMonkeypox Virus Infection1
3CompletedPrevention18-42 Year Old Healthy Vaccinia-naïve Subjects1
3CompletedPreventionHealthy Volunteers2
3CompletedPreventionSmallpox2
3RecruitingPreventionEbola1
2Active Not RecruitingPreventionEbola Virus Disease1
2Active Not RecruitingSupportive CareAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Cytomegaloviral Infection / Lymphadenopathy / Lymphoma, Hodgkins / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionSubcutaneous
Injection, suspensionSubcutaneous50000000 U.inf.
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 30, 2019 11:59 / Updated on October 31, 2020 10:29

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates